{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T21:22:14Z","timestamp":1758057734956,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejphar.2020.173271","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T20:41:59Z","timestamp":1591821719000},"page":"173271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya"],"prefix":"10.1016","volume":"882","author":[{"given":"Tomoyuki","family":"Ijiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiyoshi","family":"Kiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173271_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neulet.2004.03.058","article-title":"The timecourse of induction of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus following voluntary exercise","volume":"363","author":"Adlard","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2020.173271_bib2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","article-title":"Spinocerebellar ataxias: prospects and challenges for therapy development","volume":"14","author":"Ashizawa","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2020.173271_bib3","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1172\/JCI107339","article-title":"Metabolism and excretion of exogenous thyrotropin-releasing hormone in humans","volume":"52","author":"Bassiri","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2020.173271_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/exnr.1994.1042","article-title":"Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673","volume":"126","author":"Behrmann","year":"1994","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2020.173271_bib5","article-title":"The role of thyrotropin releasing hormone in aging and neurodegenerative diseases","volume":"1","author":"Daimon","year":"2013","journal-title":"Am. J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2020.173271_bib6","first-page":"R1196","article-title":"Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents","volume":"277","author":"Faden","year":"1999","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2020.173271_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000178727","article-title":"Peptidase inactivation of hypothalamic releasing hormones","volume":"7","author":"Griffiths","year":"1976","journal-title":"Horm. Res."},{"key":"10.1016\/j.ejphar.2020.173271_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1126\/science.212832","article-title":"Peptides in the brain: the new endocrinology of the neuron","volume":"202","author":"Guillemin","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173271_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0021-5198(19)39779-3","article-title":"Reversal of alpha-methyltyrosine-induced hypoactivity by 6-(R)-5,6,7,8-tetrahydro-L-erythrobiopterin (R-THBP) in mice","volume":"58","author":"Hirotsu","year":"1992","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173271_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev.pa.26.040186.001523","article-title":"Pharmacology of thyrotropin-releasing hormone","volume":"26","author":"Horita","year":"1986","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2020.173271_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejphar.2015.05.047","article-title":"Effect of rovatirelin, a novel thyrotropin-releasing hormone analog, on the central noradrenergic system","volume":"761","author":"Ijiro","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173271_bib12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","article-title":"Consensus paper: management of degenerative cerebellar disorders","volume":"13","author":"Ilg","year":"2014","journal-title":"Cerebellum"},{"key":"10.1016\/j.ejphar.2020.173271_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.celrep.2017.01.012","article-title":"Vulnerability of Purkinje cells generated from spinocerebellar ataxia type 6 patient-derived iPSCs","volume":"8","author":"Ishida","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2020.173271_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0014-2999(94)00712-G","article-title":"Effects of TA-0910, a novel orally active thyrotropin-releasing hormone analog, on the gait of ataxic animals","volume":"274","author":"Kinoshita","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173271_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1248\/bpb.20.36","article-title":"Chronic anti-ataxic actions of the novel thyrotropin-releasing hormone (TRH) analog, TA-0910, during and after repeated administration in Rolling mouse Nagoya: behavioral and pharmacokinetic studies","volume":"20","author":"Kinoshita","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2020.173271_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3458.1998.tb00039.x","article-title":"Taltirelin hydrate (TA-0910): an orally active thyrotropin releasing hormone mimetic agent with multiple actions","volume":"4","author":"Kinoshita","year":"1998","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2020.173271_bib18","doi-asserted-by":"crossref","first-page":"13647","DOI":"10.1021\/acsomega.8b01481","article-title":"Discovery of the orally effective thyrotropin-releasing hormone mimetic: 1-{N-[(4S,5S)-(5-Methyl-2-oxooxazolidine-4-yl)carbonyl]-3-(thiazol-4-yl)-l-alanyl}-(2R)-2-methylpyrrolidine trihydrate (rovatirelin hydrate)","volume":"3","author":"Kobayashi","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejphar.2020.173271_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/00498254.2017.1423130","article-title":"Non-clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue","volume":"49","author":"Kobayashi","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejphar.2020.173271_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0091-3057(96)00318-8","article-title":"Induction of sensitization to hyperactivity caused by morphine in mice: effects of post-drug environments","volume":"57","author":"Kuribara","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2020.173271_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainres.2006.01.031","article-title":"Spontaneous and induced mouse mutations with cerebellar dysfunctions: behavior and neurochemistry","volume":"1140","author":"Lalonde","year":"2007","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2020.173271_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/hmg\/ddy328","article-title":"Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models","volume":"28","author":"Marcelo","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2020.173271_bib23","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1523\/JNEUROSCI.20-15-05654.2000","article-title":"Reduced voltage sensitivity of activation of P\/Q-type Ca2+ channels is associated with the ataxic mouse mutation rolling Nagoya (tg(rol))","volume":"20","author":"Mori","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173271_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/0024-3205(79)90435-1","article-title":"Extra hypothalamic thyrotropin releasing hormone (TRH) \u2013 its distribution and its functions","volume":"25","author":"Morley","year":"1979","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2020.173271_bib25","first-page":"599","article-title":"The biology of pro-thyrotropin-releasing hormone-derived peptides","volume":"20","author":"Nillni","year":"1999","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2020.173271_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2019-322168","article-title":"Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials","author":"Nishizawa","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2020.173271_bib27","first-page":"281","article-title":"The observation of rolling mouse Nagoya (rol), a new neurological mutant, and its maintenance (author's transl)","volume":"22","author":"Oda","year":"1973","journal-title":"Jikken Dobutsu"},{"key":"10.1016\/j.ejphar.2020.173271_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5115\/acb.2010.43.3.211","article-title":"Differential regulation of Purkinje cell dendritic spines in rolling mouse Nagoya (tg\/tg), P\/Q type calcium channel (\u03b11(A)\/Ca(v)2.1) mutant","volume":"43","author":"Oda","year":"2010","journal-title":"Anat. Cell. Biol."},{"key":"10.1016\/j.ejphar.2020.173271_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","article-title":"Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4","volume":"87","author":"Ophoff","year":"1996","journal-title":"Cell"},{"year":"2001","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.ejphar.2020.173271_bib30"},{"key":"10.1016\/j.ejphar.2020.173271_bib31","doi-asserted-by":"crossref","first-page":"9850991","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2020.173271_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1126\/science.99816","article-title":"Aspects of hypothalamic regulation of the pituitary gland","volume":"202","author":"Schally","year":"1978","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173271_bib33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneumeth.2010.03.026","article-title":"A rotarod test for evaluation of motor skill learning","volume":"189","author":"Shiotsuki","year":"2010","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.ejphar.2020.173271_bib35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1471-4159.1977.tb10649.x","article-title":"The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat","volume":"28","author":"Sokoloff","year":"1977","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2020.173271_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1440-1789.2012.01302.x","article-title":"Reduced brain-derived neurotrophic factor (BDNF) mRNA expression and presence of BDNF-immunoreactive granules in the spinocerebellar ataxia type 6 (SCA6) cerebellum","volume":"32","author":"Takahashi","year":"2012","journal-title":"Neuropathology"},{"key":"10.1016\/j.ejphar.2020.173271_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0024-3205(02)02268-3","article-title":"Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL\/6J mice","volume":"72","author":"Urayama","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2020.173271_bib38","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","article-title":"BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice","volume":"30","author":"Xie","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2020.173271_bib39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0014-2999(89)90373-7","article-title":"Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice","volume":"166","author":"Yamamoto","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173271_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ng0197-62","article-title":"Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel","volume":"15","author":"Zhuchenko","year":"1997","journal-title":"Nat. Genet."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920303630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920303630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:38:32Z","timestamp":1757975912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920303630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"alternative-id":["S0014299920303630"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173271","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173271"}}